P1, N=20, Not yet recruiting, Lionel.D.Lewis, MD

P3, N=204, Active, not recruiting, S.L.A. Pharma AG | Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jun 2024

In vivo experiments using Hep3B xenograft models revealed that the combination of quercetin with the mitophagy inhibitor hydroxychloroquine or SIRT1 knockdown significantly enhanced the anticancer effects of quercetin, as evidenced by reduced tumor size and weight, increased necrosis and apoptosis, and decreased proliferation in tumor tissues. These findings suggest that quercetin-induced mitochondrial fusion and Pink1/Parkin-dependent mitophagy may negatively influence its anti-cancer effects in HCC. Targeting mitophagy may enhance the therapeutic potential of quercetin in HCC treatment.

P2, N=334, Not yet recruiting, Centre Hospitalier Universitaire de Saint Etienne

P4, N=70, Completed, Canadian Medical and Surgical Knowledge Translation Research Group | Active, not recruiting --> Completed

P1/2, N=120, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

In summary, given the involvement of MCOLN1-mediated autophagy in the pathogenesis of cancer and myocardial I/R injury, targeting MCOLN1 May provide clues for developing new therapeutic strategies for the treatment of these diseases. Exploring the regulation of MCOLN1-mediated autophagy in diverse diseases contexts will surely broaden our understanding of this pathway and offer its potential as a promising drug target.Abbreviation: CCCP:carbonyl cyanide3-chlorophenylhydrazone; CQ:chloroquine; HCQ: hydroxychloroquine;I/R: ischemia-reperfusion; MAP1LC3/LC3:microtubule associated protein 1 light chain 3; MCOLN1/TRPML1:mucolipin TRP cation channel 1; MLIV: mucolipidosis type IV; MTORC1:MTOR complex 1; ROS: reactive oxygenspecies; SQSTM1/p62: sequestosome 1.

P4, N=21, Active, not recruiting, Duke University | Suspended --> Active, not recruiting | N=30 --> 21 | Trial completion date: Dec 2024 --> Jun 2024 | Trial primary completion date: Dec 2024 --> May 2023

Treatment with a PLA2G7 gene inhibitor (darapladib) significantly decreased the viability of ACHN and 786-O cell lines. Additionally, we observed an association between PLA2G7 mRNA levels and various drug sensitivity. Our study suggests that PLA2G7 has the potential to serve as a valuable biomarker and therapeutic target for cancer, particularly in the context of renal cancer.

P2, N=0, Withdrawn, University of Arizona | N=24 --> 0 | Not yet recruiting --> Withdrawn

P4, N=140, Not yet recruiting, Hospices Civils de Lyon | Trial completion date: Sep 2028 --> Apr 2029 | Initiation date: Sep 2023 --> Apr 2024 | Trial primary completion date: Sep 2027 --> Apr 2028

P=N/A, N=140, Not yet recruiting, King's College Hospital NHS Trust | Initiation date: Dec 2023 --> May 2024

P1/2, N=20, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Recruiting --> Active, not recruiting

P2, N=118, Completed, ProgenaBiome | Recruiting --> Completed | Phase classification: P2a --> P2 | N=600 --> 118 | Trial completion date: Sep 2024 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Feb 2024

P=N/A, N=74, Completed, University of Sao Paulo General Hospital | Active, not recruiting --> Completed

Besides, BA initiated the formation of autophagosomes and inhibited autophagic flux by the co-administration of BA with 3-methyladenine (3-MA) and chloroquine (CQ), respectively. The in vivo experiment manifested that hydroxychloroquine (HCQ) enhanced the apoptosis induced by BA...Thus, BA could be a potential chemotherapy drug for cervical cancer, and inhibition of autophagy could enhance the anti-tumor effect of BA. However, the interactions of signaling factors between ERS-mediated and autophagy-mediated apoptosis deserve further attention.

miR-377 and phospholipase A2 have good diagnostic efficiency for the early diagnosis of diabetic kidney disease. They can be used as early biomarkers.miR-377 and phospholipase A2 were positively correlated with inflammatory factors and involved in the occurrence and development of diabetic kidney disease.

Furthermore, both in vivo and in vitro studies confirmed that suppressing the autophagic degradation of CAV1 via EC-specific ATG5 knockdown or hydroxychloroquine sulfate (HCQ) treatment significantly enhanced nab-paclitaxel translocation across the endothelial barrier into pancreatic cancer cells and amplified the inhibitory effect of nab-paclitaxel on pancreatic tumour growth. The stimulation of CAV1 expression by EC-specific overexpression of exogenous CAV1 or administration of gemcitabine hydrochloride (GE) had the same effect. These results demonstrated that suppressing CAV1 autophagic degradation is a novel translatable strategy for enhancing nab-paclitaxel chemotherapeutic activity in the treatment of pancreatic cancer.

The addition of hydroxychloroquine, an autophagy inhibitor, reduced autophagy and increased apoptosis in DLBCL cells...MiR-7-5p also suppressed autophagy and apoptosis by targeting AMBRA1 in DLBCL cells. Therefore, these data suggest that targeting miR-7-5p may be a promising strategy in DLBCL therapy.

P3, N=330, Not yet recruiting, NYU Langone Health | Initiation date: Oct 2023 --> Apr 2024

P3, N=60, Not yet recruiting, University of California, San Francisco

About half of patients with RA were on DMARDs. As expected, csDMARDs were highly used consistently. The COVID-19 pandemic might have influenced the use of HCQ and infusion DMARDs. Triple therapy use remains low.

P=N/A, N=200, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting

Macrophage-specific PLA2G7 serves as a novel biomarker capable of prognosticating immunotherapy responsiveness and inhibiting PLA2G7 has the potential to enhance the efficacy of ICB therapy for HCC.

P2, N=20, Recruiting, N.N. Petrov National Medical Research Center of Oncology

The CLEVER trial provides proof-of-principle that therapeutic targeting of dormant BC is feasible and active in eliminating DTCs by targeting dormancy-specific mechanisms. Follow up for recurrence and survival is ongoing.

P4, N=108, Recruiting, National Taiwan University Hospital | Trial primary completion date: Mar 2023 --> Dec 2024

P=N/A, N=200, Not yet recruiting, University of Wisconsin, Madison | Initiation date: Dec 2023 --> Apr 2024

P1/2, N=40, Recruiting, West Virginia University | Trial primary completion date: Jun 2023 --> Jun 2025

P1/2, N=1, Terminated, National Cancer Institute (NCI) | N=18 --> 1 | Trial completion date: Jun 2026 --> Dec 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2023; Other - Poor accrual

P2, N=187, Active, not recruiting, Milton S. Hershey Medical Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Sep 2024

P=N/A, N=21, Terminated, Washington University School of Medicine | N=30 --> 21 | Suspended --> Terminated; COVID-19 & loss of funding

P3, N=279, Active, not recruiting, Thomas M. Lietman | Recruiting --> Active, not recruiting

The third patient presented in 2003 with LP and overlying skin features of acute LE, initially responding to Plaquenil, and then four years later was diagnosed with PGD-TCL heralded by Plaquenil treatment resistance...Identifying histologic features associated with an autoimmune diathesis should not be considered exclusionary to diagnosing any panniculitis T cell lymphoma. A clinical, histomorphologic, and pathophysiologic continuum appears between LP with SPTCL and PGD-TCL of the fat.

P2/3, N=131, Completed, VA Office of Research and Development | Active, not recruiting --> Completed

P=N/A, N=50, Completed, Assiut University | Recruiting --> Completed | Trial completion date: Jun 2022 --> Jul 2023

P=N/A, N=50, Recruiting, University Hospital, Toulouse

P=N/A, N=156, Completed, Assiut University | Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Mar 2023

P3, N=418, Active, not recruiting, Mark A Hull, PhD FRCP | Recruiting --> Active, not recruiting

P3, N=58, Recruiting, Yoo-min Kim | Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Dec 2024

P1/2, N=12, Completed, St Vincent's Hospital, Sydney | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Oct 2023 | Trial primary completion date: Mar 2023 --> Aug 2023

P2, N=144, Terminated, National Institute of Allergy and Infectious Diseases (NIAID) | Completed --> Terminated; Enrollment was closed before reaching the target. In the 1st interim analysis after enrollment closure, the follow up & treatment of active participants were stopped early due to evidence of futility.